Connect your AI

TransMedics Group, Inc. TMDX Restricted Cash

Restricted Cash at other companies

Edwards LifesciencesEW

——

Other financials

Income statement

Revenue$173.9M+21.2%

Gross profit$101.2M+14.7%

Operating income$13.3M-51.5%

Net income$7.3M-71.5%

EPS (diluted)$0.20-71.4%

Balance sheet

Cash & equivalents$461.7M+48.9%

Total debt$409.9M+505%

Total equity$494.0M+85.5%

Total assets$1.4B+71.3%

Cash flow

Operating cash flow$24.5M+959%

CapEx$36.7M+35.6%

Free cash flow-$12.1M+59.4%

Valuation

Market cap$2.55B+50.6%

Enterprise value$2.5B+66.0%

P/E14.8×-19.8×

P/S4×+0.5×

Profitability

Gross margin59.1%-0.4pp

Operating margin14.9%+4.1pp

Net margin27%+17.0pp

FCF margin23.8%—

Returns & leverage

Return on equity45.2%+22.2pp

Debt / equity0.8×+0.6×

Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TransMedics Group, Inc.'s restricted cash?: TransMedics Group, Inc. (TMDX) reported restricted cash of $18.44M in Q1 2026.
How has TransMedics Group, Inc.'s restricted cash changed year-over-year?: TransMedics Group, Inc.'s restricted cash increased by 3587.6% year-over-year, from $500K to $18.44M.
What is the long-term trend for TransMedics Group, Inc.'s restricted cash?: Over 5 years (2020 to 2025), TransMedics Group, Inc.'s restricted cash has grown at a 0.0% compound annual growth rate (CAGR), from $500K to $500K.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.